The 51st Annual Meeting of the Japanese Society of Myeloma

The Evolution of Myeloma Treatment

• Shuji Ozaki
• Department of Hematology, Tokushima Prefectural Central Hospital, Japan

Current treatment algorithms of Multiple Myeloma in Japan

• Shinichi Fuchida
• Department of Hematology, JCHO Kyoto Kuramaguchi Medical Center, Japan

Global Trends in Multiple Myeloma Treatment: Implications for Therapeutic Strategies in Japan Based on International Guidelines

• Yawara Kawano
• Department of Hematology, Rheumatology, and Infectious Diseases, Graduate School of Medical Sciences, Kumamoto University, Japan

Basics and Clinics of T-cell Redirection Therapy for Multiple Myeloma

• Toshiki Ochi
• Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Japan

Real-World Experience with CAR-T Cell Therapy for Multiple Myeloma in Japan

• Taku Kikuchi
• Japanese Red Cross Medical Center

The Role of CAR-T Cell Therapy and Bispecific Antibodies in Multiple Myeloma

• Hirono Iriuchishima
• NHO Shibukawa Medical Center, Department of Clinical Research, and Hematology, Japan

Overcoming regional and resource disparities in immunotherapy for multiple myeloma in community medicine

• Sho Ikeda
• Department of Hematology, Nephrology, and Rheumatology, Akita University, Japan

Transition and Future Perspectives of Multiple Myeloma Treatment in Korea

• Sung Soo Park
• Hematology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

The progress in myeloma treatment over the 20 years since the introduction of bortezomib

• María-Victoria Mateos
• University Hospital of Salamanca, Spain

New treatment paradigms for multiple myeloma

• Philippe Moreau
• University hospital of Nantes, France

Research activities currently being conducted in KMMWP

• Sung-Hoon Jung
• Chonnam National University Hwasun Hospital, Republic of Korea

Japanese Cohort RWD Utilization in Multiple Myeloma Clinical Trials

• Masataka Takeshita
• International Myeloma Center for Advanced Research and Treatment, Department of Hematology, Tokyo-Kita Medical Center, Japan

Risk factors for skeletal-related events in multiple myeloma patients treated with denosumab

• Hirokazu Miki
• Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, Japan

Experiences for investigator-initiated international collaborative studies

• Kazuhito Suzuki
• Division of Clinical Oncology and Hematology, the Jikei University School of Medicine, Japan.

• Emiko Sakaida
• Department of Hematology, Chiba University Hospitala, Japan

Shared Decision Making in Multiple Myeloma: The Physician’s Role in an Era of Expanding Options

• Eri Kawata
• Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Japan

Shared Decision-Making in Practice and Decision Aids Using ‘O-Chi-Ta-Ka’

• Kazuhiro Nakayama
• Graduate School of Nursing Science, St. Luke's International University, Japan

A Pharmacist’s Perspective on SDM

• Hisashi Tagashira
• Department of Pharmacy, OKAYAMA Medical Center, Japan

Patient expectations of Shared Decision Making (SDM): To make informed decisions about treatment

• Kyoko Joko
• Myeloma Patients and Families, Japan

Key Considerations and Initial Management at the Introduction of Immunotherapy — Toward Establishing a Safe Treatment System —

• Kazutaka Sunami
• Department of Hematology, NHO Okayama Medical Center, Japan

Infectious Risk and Preventive Strategies in Patients with Multiple Myeloma

• Keiji Okinaka
• Division of Infectious Diseases, National Cancer Center Hospital East, Japan

Ophthalmologic Management of Anticancer Therapy–Related Ocular Toxicity and Collaboration with Hematology (Focusing on Belantamab Mafodotin)

• Toshinari Funaki
• Department of Ophthalmology, Japanese Red Cross Medical Center, Japan

Safety Management of Immunotherapy from the Pharmacist’s Perspective

• Sachiko Tada
• Department of Pharmacy. Dokkyo Medical University Saitama Medical Center

Nursing Practice that Sustains Immunotherapy: From Adverse Event Management to Long-Term Care Support

• Hisayo Doi
• Department of Nursing, Kobe University Hospital

• Hirohiko Shibayama
• Department of Hematology, NHO Osaka National Hospital

How I manage Waldenstrom macroglobulinemia in 2026

• Jorge J. Castillo
• Dana-Farber Cancer Institute, USA

MRD assessment in multiple myeloma and its therapeutic applications

• Hiroyuki Takamatsu
• Institute of Transdisciplinary Sciences for Innovation, Kanazawa University

Evolving Significance of High-Risk Cytogenetics in Multiple Myeloma in the Era of T-Cell Redirecting Therapy

• Ichiro Hanamura
• Division of Hematology, Department of Internal medicine, Aichi Medical University, Japan

Bone Marrow Microenvironment in Multiple Myeloma: Implications for Therapy and Resistance

• Hideto Tamura
• Department of Hematology, Dokkyo Medical University Saitama Medical Center

Pros

• Daisuke Minakata
• Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan

Cons

• Taku Kikuchi
• Japanese Red Cross Medical Center

Pros

• Junichiro Yuda
• National Cancer Center Hospital East Department of Hematology and Experimental Therapeutics, Japan

Cons

• Akihiro Kitadate
• Department of Hematology, Nephrology, and Rheumatology, Akita University, Japan

Clinical Implementation and Perspectives of Genomic Profiling in Multiple Myeloma

• Masataka Takeshita
• International Myeloma Center for Advanced Research and Treatment, Department of Hematology, Tokyo-Kita Medical Center, Japan

Evaluation of the clinical use of the hematologic malignancy gene panel test, HemeSight®, in multiple myeloma

• Daisuke Ogiya
• Department of Hematology and Oncology, Tokai University School of Medicine

• Hiroshi Handa
• Department of Hematology, Gunma University, Japan

• Shigeki Ito
• Hematology & Oncology, Department of Internal Medicine,Iwate Medical University, Japan

Positioning of Zanbrutinb in WM/LPL

• Hirotoshi Kamata
• Department of Hematology, Kitasato University School of Medicine

BCMA and GPRC5D as target for bispecific monoclonal antibodies in Relapsed-Refractory Myeloma

• María-Victoria Mateos
• University Hospital of Salamanca

Optimizing Treatment Sequencing and Infection Management for RRMM

• Noopur Suresh Raje
• Massachusetts General Hospital Cancer Center

The Positioning of Blenrep in Relapsed/Refractory Multiple Myeloma

• Yoichi Imai
• Department of Hematology & Onocology, Dokkyo Medical University, Japan

• Nobuhiro Tsukada
• Department of Hematology, Japanese Red Cross Medical Center

• Yoshiaki Kuroda
• Department of Transfusion Medicine Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Japan

Treatment strategy for newly diagnosed transplant-eligible multiple myeloma based on current evidence

• Hiroyuki Takamatsu
• Faculty of Transdisciplinary Sciences for Innovation, Institute of Transdisciplinary Sciences for Innovation, Kanazawa University; Department of Hematology, Kanazawa University Hospital

Current and Future Treatment Options for Waldenstrom Macroglobulinemia

• Jorge J. Castillo
• Harvard Medical School, Dana-Farber Cancer Institute, USA

Systemic AL Amyloidosis: Current Management and Future Challenges

• Yawara Kawano
• Department of Hematology, Rheumatology, and Infectious Diseases, Graduate School of Medical Sciences, Kumamoto University, Japan

Treatment Needs and the Role of Maintenance Therapy in Transplant-Ineligible Multiple Myeloma Patients

• Hitoshi Hanamoto
• Department of Hematology, Kindai University Nara Hospital

Defender in Multiple Myeloma Treatment

• Tomoki Ito
• KANSAI MEDICAL UNIVERSITY, First Department of Internal Medicine, Osaka, Japan

Treatment strategies and future challenges in multiple myeloma with extramedullary disease

• Tadao Ishida
• Department of Hematology, Japanese Red Cross Medical Center

CAR-T Cell Therapy for Multiple Myeloma: Current Status, Challenges, and Future Directions

• Junya Kuroda
• Division of Hematology and Oncology, Kyoto Prefectural University of Medicine Graduate School of Medical Science

Pleiotropic Mechanisms of Action of Carfilzomib in the Era of Immunotherapy

• Daisuke Ogiya
• Department of Hematology and Oncology, Tokai University School of Medicine

Positioning of Carfilzomib as an Early-Line Treatment Strategy in Multiple Myeloma

• Daisuke Minakata
• Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan

Anti-BCMA Bispecific Antibodies : What's New Over Two Years

• Teruhito Takakuwa
• Department of Hematology, Wakakusa Daiichi Hospital

Patient management and Work coordination in a specialized hematology cIinic

• Miyuki Nishiura
• HematoIogy Ohta Clinic, shinsaibashi

Current Updates in M-Protein Assessment in Multiple Myeloma and Related Disorders

• Yawara Kawano
• Department of Hematology, Rheumatology, and Infectious Diseases, Graduate School of Medical Sciences, Kumamoto University, Japan

The potential benefits and risks of quadruplet therapy for TIE-NIDDM

• Tomohiko Kamimura
• Department of Hematology, Harasanshin Hospital

Cold Agglutinin Disease and Differential Diagnosis from the Perspective of a Pathologist

• Masako Kurashige
• Department of Pathology, Graduate School of Medicine, The University of Osaka

The Ultimate Guide to CAD's Diverse Symptoms, Disease Burden, and Treatment

• Jun-ichi Nishimura
• Department of Hematology and Oncology, The University of Osaka Graduate School of Medicine, Japan

Deciphering the Diverse Therapeutic Landscape of Multiple Myeloma Through Genomic Alteration

• Ryosuke Shirasaki
• Department of Hematology/Oncology, Teikyo University School of Medicine, Japan